{"entity":{"type":"insider","cik":"0001536053","url":"/insider/0001536053","json_url":"/insider/0001536053.json","name":"Schiller Howard Bradley","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":6,"first":"2011-12-05","last":"2012-11-08","span_basis":"filed_date"},"name_variants":[{"name":"Schiller Howard Bradley","source":"filing","n_filings":6,"first_seen":"2011-12-05","last_seen":"2012-11-08"}],"transactions":[{"id":3428916,"accession":"0000885590-12-000072","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000885590-12-000072","line_url":"/filing/0000885590-12-000072#line-1","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18300.0,"shares_display":"18,300","price_per_share":54.104,"price_display":"54.10","price_state":"stated","total_value":990103.2,"total_display":"990,103.20","total_whole":"990,103","shares_owned_after":182900.0,"shares_owned_after_display":"182,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-11-06","filed_date":"2012-11-08","scope":"insider"},{"id":2180466,"accession":"0000885590-12-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000885590-12-000011","line_url":"/filing/0000885590-12-000011#line-1","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (CFO)","role_mark":"O","role_mark_label":"Officer (CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9200.0,"shares_display":"9,200","price_per_share":53.5276,"price_display":"53.53","price_state":"stated","total_value":492453.92,"total_display":"492,453.92","total_whole":"492,454","shares_owned_after":136800.0,"shares_owned_after_display":"136,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-06","filed_date":"2012-03-08","scope":"insider"},{"id":3322324,"accession":"0000885590-12-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000885590-12-000010","line_url":"/filing/0000885590-12-000010#line-2","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9300.0,"shares_display":"9,300","price_per_share":53.8107,"price_display":"53.81","price_state":"stated","total_value":500439.51,"total_display":"500,439.51","total_whole":"500,440","shares_owned_after":127600.0,"shares_owned_after_display":"127,600","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-02","filed_date":"2012-03-05","scope":"insider"},{"id":3322320,"accession":"0000885590-12-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000885590-12-000010","line_url":"/filing/0000885590-12-000010#line-1","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9300.0,"shares_display":"9,300","price_per_share":53.4717,"price_display":"53.47","price_state":"stated","total_value":497286.81,"total_display":"497,286.81","total_whole":"497,287","shares_owned_after":118300.0,"shares_owned_after_display":"118,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-01","filed_date":"2012-03-05","scope":"insider"},{"id":8962079,"accession":"0000885590-11-000085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000885590-11-000085","line_url":"/filing/0000885590-11-000085#line-1","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11000.0,"shares_display":"11,000","price_per_share":45.5096,"price_display":"45.51","price_state":"stated","total_value":500605.6,"total_display":"500,605.60","total_whole":"500,606","shares_owned_after":54500.0,"shares_owned_after_display":"54,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-08","filed_date":"2011-12-09","scope":"insider"},{"id":9087800,"accession":"0000885590-11-000083","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000885590-11-000083","line_url":"/filing/0000885590-11-000083#line-1","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11000.0,"shares_display":"11,000","price_per_share":46.82,"price_display":"46.82","price_state":"stated","total_value":515020.0,"total_display":"515,020.00","total_whole":"515,020","shares_owned_after":43500.0,"shares_owned_after_display":"43,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-05","filed_date":"2011-12-07","scope":"insider"},{"id":9010418,"accession":"0000885590-11-000082","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000885590-11-000082","line_url":"/filing/0000885590-11-000082#line-2","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11000.0,"shares_display":"11,000","price_per_share":46.26,"price_display":"46.26","price_state":"stated","total_value":508860.0,"total_display":"508,860.00","total_whole":"508,860","shares_owned_after":32500.0,"shares_owned_after_display":"32,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-02","filed_date":"2011-12-05","scope":"insider"},{"id":9010417,"accession":"0000885590-11-000082","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000885590-11-000082","line_url":"/filing/0000885590-11-000082#line-1","is_derivative":false,"issuer_cik":"0000885590","issuer_name":"Valeant Pharmaceuticals International, Inc.","issuer_ticker":"VRX","issuer_name_source":null,"issuer_url":"/issuer/0000885590","owner_cik":"0001536053","owner_name":"Schiller Howard Bradley","owner_display_name":"Schiller Howard Bradley","owner_url":"/insider/0001536053","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21500.0,"shares_display":"21,500","price_per_share":46.05,"price_display":"46.05","price_state":"stated","total_value":990075.0,"total_display":"990,075.00","total_whole":"990,075","shares_owned_after":21500.0,"shares_owned_after_display":"21,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-01","filed_date":"2011-12-05","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":8,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000885590","name":"Valeant Pharmaceuticals International, Inc.","url":"/issuer/0000885590","role":"Officer (EVP and CFO)","n_filings":6,"first_seen":"2011-12-05","last_seen":"2012-11-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001536053","retrieved_at":"2026-08-23T03:59:11+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}